CCA
FLGT icon

Catalyst Capital Advisors’s Fulgent Genetics FLGT Stock Holding History

Catalyst Capital Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-358
Closed -$4K – 528
2016
Q4 		$4K Hold
358
– – ﹤0.01% 355
2016
Q3 		$3K Buy
+358
New +$3.29K ﹤0.01% 399

Other funds holding FLGT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SC
Scholtz & Company Stamford, Connecticut $195M AUM 12.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NFA
Nationwide Fund Advisors Columbus, Ohio $2.42B AUM 17.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Capital Advisors's FLGT Position: Q1 2017 in Review

Catalyst Capital Advisors sold out of Fulgent Genetics (FLGT) in Q1 2017, closing a stake of 358 shares — an estimated $4K sold.

Catalyst Capital Advisors first reported a position in FLGT in Q3 2016 and held it in 2 quarters. The position peaked at $4K in Q4 2016. 37 funds tracked by Wall St. Rank hold FLGT as of Q1 2017.

  • Catalyst Capital Advisors reported no remaining Fulgent Genetics position as of Q1 2017 after selling out during the quarter.
  • Catalyst Capital Advisors sold 358 Fulgent Genetics shares in Q1 2017, an estimated $4K.
  • Catalyst Capital Advisors first reported a position in Fulgent Genetics in Q3 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's Fulgent Genetics position peaked at $4K in Q4 2016.
  • 37 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2017.

Based on Catalyst Capital Advisors's 13F filing for Q1 2017, filed 9 May 2017.